دورية أكاديمية
أعرض في EDS

COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years - United States, June 20-December 31, 2022.

التفاصيل البيبلوغرافية
العنوان: COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years - United States, June 20-December 31, 2022.
المؤلفون: Murthy BP, Fast HE, Zell E, Murthy N, Meng L, Shaw L, Vogt T, Chatham-Stephens K, Santibanez TA, Gibbs-Scharf L, Harris LQ
المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2023 Feb 17; Vol. 72 (7), pp. 183-189. Date of Electronic Publication: 2023 Feb 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: Atlanta, GA : U.S. Centers for Disease Control
Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control.
مواضيع طبية MeSH: COVID-19 Vaccines* , COVID-19*/epidemiology , COVID-19*/prevention & control, Infant ; United States/epidemiology ; Humans ; Child ; Adolescent ; Aged ; Vaccination Coverage ; 2019-nCoV Vaccine mRNA-1273 ; BNT162 Vaccine ; Vaccination ; District of Columbia ; Demography
مستخلص: Although severe COVID-19 illness and hospitalization are more common among older adults, children can also be affected (1). More than 3 million cases of COVID-19 had been reported among infants and children aged <5 years (children) as of December 2, 2022 (2). One in four children hospitalized with COVID-19 required intensive care; 21.2% of cases of COVID-19-related multisystem inflammatory syndrome in children (MIS-C) occurred among children aged 1-4 years, and 3.2% of MIS-C cases occurred among infants aged <1 year (1,3). On June 17, 2022, the Food and Drug Administration issued an Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine for children aged 6 months-5 years and the Pfizer-BioNTech COVID-19 vaccine for children aged 6 months-4 years. To assess COVID-19 vaccination coverage among children aged 6 months-4 years in the United States, coverage with ≥1 dose* and completion of the 2-dose or 3-dose primary vaccination series † were assessed using vaccine administration data for the 50 U.S. states and District of Columbia submitted from June 20 (after COVID-19 vaccine was first authorized for this age group) through December 31, 2022. As of December 31, 2022, ≥1-dose COVID-19 vaccination coverage among children aged 6 months-4 years was 10.1% and was 5.1% for series completion. Coverage with ≥1 dose varied by jurisdiction (range = 2.1% [Mississippi] to 36.1% [District of Columbia]) as did coverage with a completed series (range = 0.7% [Mississippi] to 21.4% [District of Columbia]), respectively. By age group, 9.7 % of children aged 6-23 months and 10.2% of children aged 2-4 years received ≥1 dose; 4.5% of children aged 6-23 months and 5.4% of children aged 2-4 years completed the vaccination series. Among children aged 6 months-4 years, ≥1-dose COVID-19 vaccination coverage was lower in rural counties (3.4%) than in urban counties (10.5%). Among children aged 6 months-4 years who received at least the first dose, only 7.0% were non-Hispanic Black or African American (Black), and 19.9% were Hispanic or Latino (Hispanic), although these demographic groups constitute 13.9% and 25.9% of the population, respectively (4). COVID-19 vaccination coverage among children aged 6 months-4 years is substantially lower than that among older children (5). Efforts are needed to improve vaccination coverage among children aged 6 months-4 years to reduce COVID-19-associated morbidity and mortality.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
References: JAMA Pediatr. 2022 Feb 1;176(2):201-203. (PMID: 34870702)
Vital Health Stat 2. 2014 Apr;(166):1-73. (PMID: 24776070)
Clin Infect Dis. 2022 Aug 24;75(1):e1165-e1175. (PMID: 34864955)
Emerg Infect Dis. 2022 May;28(5):986-989. (PMID: 35226801)
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):429-436. (PMID: 35298458)
المشرفين على المادة: 0 (COVID-19 Vaccines)
EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
0 (BNT162 Vaccine)
SCR Disease Name: pediatric multisystem inflammatory disease, COVID-19 related
تواريخ الأحداث: Date Created: 20230216 Date Completed: 20230222 Latest Revision: 20230225
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9949848
DOI: 10.15585/mmwr.mm7207a4
PMID: 36795658
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-861X
DOI:10.15585/mmwr.mm7207a4